Navigation Links
Quest Diagnostics Announces Pricing in Offering of Common Stock by the Company's Largest Shareholder
Date:2/1/2011

MADISON, N.J., Feb. 1, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced the pricing of the previously announced secondary public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK") at a price to the public of $56.25.  

Quest Diagnostics has not sold any shares of common stock in the offering and will not receive any of the proceeds from the sale of shares in the offering.

Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are joint bookrunners for the offering. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities.  A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective.  A written prospectus for this offering meeting the requirements of Section 10 of the Securities Act of 1933 (other than a free writing prospectus as defined in Securities Act Rule 405) may be obtained from Deutsche Bank Securities Inc., 100 Plaza One, Jersey City, N.J. 07311 or by calling 1-800-503-4611, or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 1-866-803-9204.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Contacts for Quest Diagnostics: Kathleen Valentine (Investors), +1-973-520-2900, or Gary Samuels, (Media), +1-973-520-2800


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... the quarter ended June 30, 2017.  All comparisons, unless otherwise ... Second Quarter 2017 Highlights ... to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... , Aug. 4, 2017 The search ... shortly after a physician/patient consult has long been the ... was a notable focus of the largest meeting of ... according to healthcare market research firm Kalorama Information.  The ... testing (POCT) offerings or related supplies and software were ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... 2017 , ... Nightingale College continues the semiannual Give Back Day tradition for ... College dedicates to serving and volunteering for organizations that provide indispensable resources to the ... that need a little extra help. , The College’s Give Back Day initiative ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, the nation's ... the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks ... percent, marking the twelfth year that the company has been included on the ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... (SNAC) is holding an inaugural State of the Science Symposium in partnership ... Wednesday, Sept. 20, 2017. , This symposium provides a forum for global leaders ...
(Date:8/22/2017)... NASHVILLE, Tenn. (PRWEB) , ... August 22, 2017 ... ... Company, is pleased to announce the addition of Zack Tisch as the ... services for the KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients ...
Breaking Medicine News(10 mins):